...
首页> 外文期刊>Journal of Clinical Oncology >Questionable universal validity of PAX3/FOXO1 fusion gene status as molecular marker for improvement of risk stratification in rhabdomyosarcoma therapy
【24h】

Questionable universal validity of PAX3/FOXO1 fusion gene status as molecular marker for improvement of risk stratification in rhabdomyosarcoma therapy

机译:PAX3 / FOXO1融合基因状态作为改善横纹肌肉瘤风险分层的分子标志物的普遍有效性存疑

获取原文
获取原文并翻译 | 示例
           

摘要

To the Editor: It was of particular interest to us to read that the PAX3/FOXO1 fusion gene is considered to be the key molecular risk factor in rhabdomyosarcoma (RMS), as recently reported by Missia-gliaetal.One previous analysis from the International Society of Pediatric Oncology (SIOP)2 and several from the Children's Oncology Group (COG) have discussed the potential prognostic value of PAX/ FOXO1 fusion status.
机译:致编辑:我们特别感兴趣的是,正如Missia-gliaetal最近报道的那样,PAX3 / FOXO1融合基因被认为是横纹肌肉瘤(RMS)的关键分子危险因素。国际社会以前的一项分析儿科肿瘤学(SIOP)2和儿童肿瘤学组(COG)的几位专家讨论了PAX / FOXO1融合状态的潜在预后价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号